The global Gene Therapy Starting Materials Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Product (Viral Vectors, Plasmid DNA, Cell Lines, Others), By Development Stage (Pre-clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics), By Application (Oncology, Infectious Disease, Genetic Disease, Others), By End-User (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Others).
The gene therapy starting materials market is witnessing robust growth in 2025, underpinned by a wave of approved gene therapies and a burgeoning pipeline of clinical candidates. Critical starting materials include plasmid DNA, viral vectors (such as AAV, lentivirus, and adenovirus), synthetic nucleotides, and gene editing components like CRISPR/Cas systems. Manufacturers of starting materials must meet extremely stringent quality, purity, and regulatory requirements (cGMP-grade production), given the direct integration into human therapies. Capacity constraints, particularly for viral vectors, are leading to significant investments in expanding manufacturing facilities and adopting modular, flexible production technologies. Emerging trends such as non-viral delivery systems and novel genome editing approaches are diversifying the types of starting materials in demand. Strategic collaborations between biotech firms, CDMOs (Contract Development and Manufacturing Organizations), and academic institutions are critical to overcoming supply bottlenecks. As regulatory agencies introduce expedited pathways for gene therapies, the need for reliable, high-quality starting materials will remain a major growth engine for this market.
The market report analyses the leading companies in the industry including Catalent, Charles River Laboratories, Danaher, Eurofins Scientific, GenScript, Lonza, Merck KGaA, Revvity Inc, Sartorius AG, Thermo Fisher Scientific Inc, and others.
A growing trend in the gene therapy starting materials market is the increasing adoption of synthetic and cell-free manufacturing platforms for plasmids, viral vectors, and mRNA components. Traditional cell culture methods are facing scalability and contamination challenges, prompting innovators to invest in cleaner, faster, and more controllable synthetic production routes. This trend is not only accelerating manufacturing timelines but is also enhancing the consistency and regulatory compliance of gene therapy products entering clinical and commercial pipelines.
The rapid expansion of clinical trials and approvals for gene therapies targeting both rare genetic disorders and more common conditions, such as hemophilia and certain cancers, is driving demand for high-quality starting materials. Gene therapy developers require GMP-grade plasmids, viral vectors, and nucleotides that meet rigorous safety and efficacy standards. As more gene therapies move from discovery into late-stage development and commercialization, the pressure on supply chains to deliver reliable, scalable starting materials continues to intensify.
There is a major opportunity for companies to develop modular, on-demand production platforms for gene therapy starting materials. Solutions that allow flexible, small-batch production tailored to specific gene constructs or patient-specific therapies will be highly valuable, especially for personalized medicine applications. Such platforms would address bottlenecks in current centralized manufacturing models and provide agility for biotech companies needing rapid turnaround for preclinical and early-phase programs.
The Viral Vectors segment is projected to lead the gene therapy starting materials market in 2025, fueled by their crucial role as delivery vehicles in a wide range of gene therapy applications, particularly in oncology, rare genetic disorders, and regenerative medicine. Viral vectors, such as lentivirus, adeno-associated virus (AAV), and retrovirus, have demonstrated superior efficiency in delivering therapeutic genes to target cells with high specificity and stability. The surge in FDA approvals for gene therapies, along with robust pipelines from biotech and pharmaceutical companies, is accelerating the demand for clinical-grade viral vectors. Moreover, significant investments in vector manufacturing infrastructure and the development of scalable production technologies are driving cost efficiency and supply reliability. Given their indispensable role in both clinical and commercial gene therapy products, viral vectors will continue to dominate the market’s revenue share through 2025.
The clinical therapeutics segment is projected to experience the fastest growth in the gene therapy starting materials market through 2034, driven by the rapid expansion of gene therapy clinical trials across rare diseases, oncology, and inherited disorders. As pharmaceutical and biotech companies advance from preclinical studies to human trials, the demand for high-quality viral vectors, plasmid DNA, and reagents intensifies, especially under stringent GMP standards. A significant number of gene therapy candidates are now in Phase I and II pipelines globally, signaling robust growth in material consumption during early- and mid-stage clinical development. Moreover, increasing regulatory support for accelerated approvals and orphan drug designations is encouraging innovation and scaling of clinical-grade materials. The surge in investments from both public institutions and private venture capitalists further reinforces this segment's momentum, positioning it as the core growth engine in the gene therapy starting materials market.
China’s Gene Therapy Starting Materials Market is experiencing robust growth, driven by the country's rapid advancements in biotechnology and pharmaceutical sectors. The Chinese government’s strong support for biotechnology innovations, such as through the National Key R&D Program, is fostering a conducive environment for the development of gene therapies. With a growing focus on personalized medicine and a rising prevalence of genetic disorders, China is positioning itself as a leader in the gene therapy space, driving demand for starting materials like viral vectors, plasmids, and other gene-editing tools. Additionally, the expansion of healthcare infrastructure and research capabilities in China is enhancing the availability of gene therapy products, including raw materials for clinical trials and commercial production. As China becomes increasingly integrated into the global biotechnology ecosystem, collaboration with international firms is expected to accelerate advancements in gene therapy technologies. However, challenges such as regulatory hurdles, the need for stringent quality control measures, and the high cost of production may present barriers to full-scale commercialization in the near term.
India's Gene Therapy Starting Materials Market is expanding due to the country's increasing investments in biotechnology and an emerging focus on genetic research and therapeutics. With rising incidences of genetic disorders and chronic diseases such as cancer and hemophilia, India is seeing greater adoption of gene therapies as an innovative treatment approach. The government’s initiatives to improve healthcare access and strengthen biotechnology infrastructure are fueling the demand for high-quality gene therapy starting materials, including viral vectors, CRISPR-Cas9 components, and plasmids. India’s strong pharmaceutical manufacturing base, cost-competitive advantages, and a growing number of clinical trials in gene therapy are boosting the country’s market growth. Additionally, collaboration with global biotech firms and academic institutions is driving the development and supply chain of gene therapy materials. However, challenges such as limited infrastructure, regulatory complexities, and the high cost of gene therapies could impede rapid market growth, especially in the country’s rural areas.
The United States dominates the Gene Therapy Starting Materials Market, benefiting from its strong biotechnology sector and leadership in the development of gene-based treatments. The U.S. has been at the forefront of gene therapy advancements, with numerous gene therapy products already in clinical use and several others in the pipeline. This has driven a growing demand for essential starting materials like viral vectors, plasmids, and other gene-editing tools. The U.S. Food and Drug Administration (FDA) plays a pivotal role in ensuring the safety and efficacy of gene therapies, thus creating a favorable regulatory environment for the development and commercialization of gene therapy products. Additionally, the U.S. has extensive research infrastructure, with universities, pharmaceutical companies, and biotech firms collaborating to create cutting-edge gene therapies. The high level of private and public investment in biotech innovation, as well as the increasing prevalence of genetic diseases, has positioned the U.S. as a global leader in the gene therapy materials market. However, challenges include the high cost of gene therapies, regulatory hurdles, and supply chain bottlenecks related to the production of high-quality starting materials.
Germany’s Gene Therapy Starting Materials Market is growing as a result of the country’s strong pharmaceutical and biotechnology industries. As one of the largest markets in Europe, Germany benefits from its advanced healthcare infrastructure and well-established regulatory frameworks, which facilitate the development and commercialization of gene therapies. The demand for starting materials such as viral vectors, plasmids, and gene-editing tools is rising, driven by the increasing number of gene therapy trials and the need for customized therapeutic approaches in treating genetic diseases. The German government has been investing in biotechnology research, ensuring the availability of funding for gene therapy advancements and strengthening the country’s position as a leader in European biotech. Additionally, Germany’s participation in the European Medicines Agency (EMA) and its collaboration with other European countries further stimulate the development of gene therapy products. However, the complexity of gene therapy production processes and the need for specialized raw materials may drive up costs, limiting widespread adoption in some market segments.
France’s Gene Therapy Starting Materials Market is seeing an upward trajectory, driven by the country’s growing biotechnology research capabilities and its robust healthcare system. The French government is heavily investing in biotechnology and gene therapy, which is resulting in an increasing number of research and clinical trials focused on genetic disorders such as cystic fibrosis, muscular dystrophy, and rare diseases. As a result, the demand for essential gene therapy starting materials, including viral vectors and plasmids, is on the rise. France’s strong pharmaceutical manufacturing sector and its support for precision medicine are further fueling the growth of the gene therapy market. Additionally, France’s involvement in European collaborative projects and access to EU funding for biotech research are helping to advance the development of gene therapies and the associated supply chain for raw materials. However, high costs, technical challenges in scaling up production, and regulatory complexities may pose significant hurdles in market growth, especially when compared to other established markets like the U.S.
The Gene Therapy Starting Materials Market in the Middle East is in the early stages of development but is expected to experience significant growth as healthcare in the region continues to modernize. Countries like the UAE, Saudi Arabia, and Qatar are heavily investing in their healthcare sectors, with an increasing focus on biotechnology and personalized medicine. The rising prevalence of genetic diseases, coupled with an increasing number of research initiatives in gene therapy, is creating demand for raw materials required for gene therapies, including viral vectors, CRISPR technology, and plasmids. Additionally, partnerships with global pharmaceutical and biotech firms, coupled with government support for health innovation, are helping to boost the availability and production of gene therapy starting materials in the region. However, challenges such as a lack of infrastructure, regulatory hurdles, and high production costs for gene therapies could hinder market growth in the short term. Over time, as the region's healthcare systems improve and the demand for advanced therapeutic solutions grows, the Middle East market is expected to witness strong expansion in gene therapy-related materials.
|
Parameter |
Details |
|
Market Size (2025) |
$2.8 Billion |
|
Market Size (2034) |
$13.5 Billion |
|
Market Growth Rate |
19.1% |
|
Segments |
By Product (Viral Vectors, Plasmid DNA, Cell Lines, Others), By Development Stage (Pre-clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics), By Application (Oncology, Infectious Disease, Genetic Disease, Others), By End-User (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Others) |
|
Study Period |
2019- 2024 and 2025-2034 |
|
Units |
Revenue (USD) |
|
Qualitative Analysis |
Porter’s Five Forces, SWOT Profile, Market Share, Scenario Forecasts, Market Ecosystem, Company Ranking, Market Dynamics, Industry Benchmarking |
|
Companies |
Catalent, Charles River Laboratories, Danaher, Eurofins Scientific, GenScript, Lonza, Merck KGaA, Revvity Inc, Sartorius AG, Thermo Fisher Scientific Inc |
|
Countries |
US, Canada, Mexico, Germany, France, Spain, Italy, UK, Russia, China, India, Japan, South Korea, Australia, South East Asia, Brazil, Argentina, Middle East, Africa |
By Product
Viral Vectors
-Adenovirus
-Retrovirus
-Adeno-Associated Virus (AAV)
-Lentivirus
-Others
Plasmid DNA
Cell Lines
Others
By Development Stage
Pre-clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Application
Oncology
Infectious Disease
Genetic Disease
Others
By End-User
Biopharmaceutical & Pharmaceutical Companies
CROs & CMOs
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Catalent
Charles River Laboratories
Danaher
Eurofins Scientific
GenScript
Lonza
Merck KGaA
Revvity Inc
Sartorius AG
Thermo Fisher Scientific Inc
*- List Not Exhaustive
About USD Analytics
Table of Contents
List of Charts and Exhibits
List of Tables
1. Executive Summary
What’s New in 2025?
Top 10 Takeaways from the industry
Potential Opportunities for Industry Stakeholders
Strategic Imperatives
Company Market Positioning
Industry Benchmarking Matrix
2. Research Scope and Methodology
Market Definition
- Market Segments
- Companies Profiled
Research Methodology
- Bottom-Up Method
- Top-Down Method
- Data Triangulation
Forecast Methodology
- Data Sources
- USDA Proprietary Databases
- External Sources
- Primary Research and Interviews
Conversion Rates for USD
Abbreviations
3. Strategic Landscape: Key Insights and Implications
Spotlight: Key Strategies opted by Business Leaders
Competitive Landscape
Market Size ($ Million) and Share (%) by Company, 2024
SWOT Analysis
- Key Market Strengths
- Key Market Weaknesses
- Potential Opportunities
- Potential Threats
Porter’s Five Force Analysis
- Summary
- Bargaining Power of Buyers- Impact Analysis
- Bargaining Power of Suppliers- Impact Analysis
- Threat of new entrants- Impact Analysis
- Intensity of Competitive Rivalry- Impact Analysis
Macro-Environmental Analysis
- Economic forecasts by Country, 2010- 2035
- Population forecasts by Country, 2010- 2035
- Inflation Outlook by Country, 2010-2035
- Impact of Russia-Ukraine Conflict, Sluggish China Growth, US Developments
5. Growth Opportunity Analysis
Trends at a Glance
- What are the most noteworthy trends in the market
- Where should leaders pay attention?
- What industries are likely to be affected by the growth?
Market Dynamics
- Charting a path forward
- Growth Drivers
- Growth Barriers
Key Industry Stakeholders
- Suppliers
- Manufacturers and Service Providers
- Distribution Channels
- End-Users and Applications
- Regulators
- Investors, Traders, and R&D Institutes
Regulatory Landscape
6. Market Size Outlook to 2034
Global Gene Therapy Starting Materials Market Size Forecast, USD Million, 2018- 2034
- Historic Market Size, 2018- 2024
- Forecast Market Size, 2024- 2034
Scenario Analysis
- Low Growth Scenario: Definition and Outlook to 2034
- Reference Case: Definition and Outlook to 2034
- High Growth Scenario: Definition and Outlook to 2034
Pricing Analysis and Outlook
- Gene Therapy Starting Materials Average Price Forecast, 2021- 2034
- Key Factors Shaping the Pricing Patterns
7. Historical Gene Therapy Starting Materials Market Size by Segments, 2018- 2024
Key Statistics, 2024
Gene Therapy Starting Materials Market Size Outlook by Type, USD Million, 2018- 2024
Growth Comparison (y-o-y) across Gene Therapy Starting Materials Types, 2018- 2024
Gene Therapy Starting Materials Market Size Outlook by Application, USD Million, 2018- 2024
Growth Comparison (y-o-y) across Gene Therapy Starting Materials Applications, 2018- 2024
8. Gene Therapy Starting Materials Market Size Outlook by Segments, 2024- 2034
By Product
Viral Vectors
-Adenovirus
-Retrovirus
-Adeno-Associated Virus (AAV)
-Lentivirus
-Others
Plasmid DNA
Cell Lines
Others
By Development Stage
Pre-clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Application
Oncology
Infectious Disease
Genetic Disease
Others
By End-User
Biopharmaceutical & Pharmaceutical Companies
CROs & CMOs
Others
9. Gene Therapy Starting Materials Market Size Outlook by Region
North America
Key Market Dynamics
North America Gene Therapy Starting Materials Market Size Outlook by Type, USD Million, 2021-2034
North America Gene Therapy Starting Materials Market Size Outlook by Application, USD Million, 2021-2034
North America Gene Therapy Starting Materials Market Size Outlook by Sales Channel, USD Million, 2021-2034
North America Gene Therapy Starting Materials Market Size Outlook by Country, USD Million, 2021-2034
Europe
Key Market Dynamics
Europe Gene Therapy Starting Materials Market Size Outlook by Type, USD Million, 2021-2034
Europe Gene Therapy Starting Materials Market Size Outlook by Application, USD Million, 2021-2034
Europe Gene Therapy Starting Materials Market Size Outlook by Sales Channel, USD Million, 2021-2034
Europe Gene Therapy Starting Materials Market Size Outlook by Country, USD Million, 2021-2034
Asia Pacific
Key Market Dynamics
Asia Pacific Gene Therapy Starting Materials Market Size Outlook by Type, USD Million, 2021-2034
Asia Pacific Gene Therapy Starting Materials Market Size Outlook by Application, USD Million, 2021-2034
Asia Pacific Gene Therapy Starting Materials Market Size Outlook by Sales Channel, USD Million, 2021-2034
Asia Pacific Gene Therapy Starting Materials Market Size Outlook by Country, USD Million, 2021-2034
South America
Key Market Dynamics
South America Gene Therapy Starting Materials Market Size Outlook by Type, USD Million, 2021-2034
South America Gene Therapy Starting Materials Market Size Outlook by Application, USD Million, 2021-2034
South America Gene Therapy Starting Materials Market Size Outlook by Sales Channel, USD Million, 2021-2034
South America Gene Therapy Starting Materials Market Size Outlook by Country, USD Million, 2021-2034
Middle East and Africa
Key Market Dynamics
Middle East and Africa Gene Therapy Starting Materials Market Size Outlook by Type, USD Million, 2021-2034
Middle East and Africa Gene Therapy Starting Materials Market Size Outlook by Application, USD Million, 2021-2034
Middle East and Africa Gene Therapy Starting Materials Market Size Outlook by Sales Channel, USD Million, 2021-2034
Middle East and Africa Gene Therapy Starting Materials Market Size Outlook by Country, USD Million, 2021-2034
10. United States Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
United States Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
United States Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
United States Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
11. Canada Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Canada Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Canada Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Canada Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
12. Mexico Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Mexico Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Mexico Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Mexico Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
13. Germany Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Germany Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Germany Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Germany Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
14. France Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
France Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
France Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
France Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
15. United Kingdom Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
United Kingdom Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
United Kingdom Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
United Kingdom Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
16. Spain Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Spain Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Spain Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Spain Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
17. Italy Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Italy Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Italy Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Italy Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
18. Benelux Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Benelux Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Benelux Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Benelux Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
19. Nordic Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Nordic Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Nordic Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Nordic Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
20. Rest of Europe Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of Europe Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Rest of Europe Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Rest of Europe Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
21. China Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
China Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
China Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
China Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
22. India Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
India Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
India Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
India Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
23. Japan Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Japan Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Japan Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Japan Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
24. South Korea Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
South Korea Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
South Korea Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
South Korea Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
25. Australia Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Australia Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Australia Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Australia Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
26. South East Asia Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
South East Asia Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
South East Asia Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
South East Asia Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
27. Rest of Asia Pacific Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of Asia Pacific Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Rest of Asia Pacific Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Rest of Asia Pacific Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
28. Brazil Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Brazil Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Brazil Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Brazil Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
29. Argentina Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Argentina Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Argentina Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Argentina Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
30. Rest of South America Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of South America Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Rest of South America Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Rest of South America Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
31. United Arab Emirates Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
United Arab Emirates Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
United Arab Emirates Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
United Arab Emirates Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
32. Saudi Arabia Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Saudi Arabia Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Saudi Arabia Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Saudi Arabia Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
33. Rest of Middle East Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of Middle East Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Rest of Middle East Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Rest of Middle East Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
34. South Africa Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
South Africa Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
South Africa Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
South Africa Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
35. Rest of Africa Gene Therapy Starting Materials Market Analysis and Outlook, 2021- 2034
Key Statistics
Rest of Africa Gene Therapy Starting Materials Market Size Outlook by Type, 2021- 2034
Rest of Africa Gene Therapy Starting Materials Market Size Outlook by Application, 2021- 2034
Rest of Africa Gene Therapy Starting Materials Market Size Outlook by End-User, 2021- 2034
36. Key Companies
Market Share Analysis
Catalent
Charles River Laboratories
Danaher
Eurofins Scientific
GenScript
Lonza
Merck KGaA
Revvity Inc
Sartorius AG
Thermo Fisher Scientific Inc
Company Benchmarking
Financial Analysis
37. Recent Market Developments
38. Appendix
Looking Ahead
Research Methodology
Legal Disclaimer
By Product
Viral Vectors
-Adenovirus
-Retrovirus
-Adeno-Associated Virus (AAV)
-Lentivirus
-Others
Plasmid DNA
Cell Lines
Others
By Development Stage
Pre-clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Application
Oncology
Infectious Disease
Genetic Disease
Others
By End-User
Biopharmaceutical & Pharmaceutical Companies
CROs & CMOs
Others
The Global Gene Therapy Starting Materials Market Size is estimated at $2.8 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 19.1% to reach $13.5 Billion by 2034.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Catalent, Charles River Laboratories, Danaher, Eurofins Scientific, GenScript, Lonza, Merck KGaA, Revvity Inc, Sartorius AG, Thermo Fisher Scientific Inc
Base Year- 2024; Estimated Year- 2025; Historic Period- 2019-2024; Forecast period- 2025 to 2034; Currency: Revenue (USD); Volume